Reading Time: 5 minutesThis blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters
Category: Clinical Trials
Reading Time: 2 minutesThis blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters
Reading Time: 4 minutesThis blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters
Reading Time: 3 minutesA centaur was a creature from Greek mythology which was half-man and half-horse. Despite such an unusual appearance such a combination could have its advantages.
Reading Time: 2 minutesThis week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Reading Time: 5 minutesLast Thursday marked an exciting milestone in the search for effective therapies for MND as full results from the early-phase 1/2 trial of Biogen’s tofersen
Reading Time: 4 minutesAlthough ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in
Reading Time: 5 minutesThis blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 4 minutesThis blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 3 minutesTUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure